Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Emfizatamab by Systimmune for Non-Hodgkin Lymphoma: Likelihood of Approval
Emfizatamab is under clinical development by Systimmune and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...
Data Insights
Emfizatamab by Systimmune for Solid Tumor: Likelihood of Approval
Emfizatamab is under clinical development by Systimmune and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...